In this week’s edition of InnovationRx, we look at cheaper biologic drugs, Novo Nordisk’s $2 billion next-gen obesity drug deal, new ways of fighting cancer, and more.Since 2015, more than 90 ‘biosimilars’–cheaper versions of off-patent branded biologic drugs–have gained FDA approval. Nearly 25 more should gain approval over the next two years, in areas that […]
